Menarini Group to present new elacestrant and tagraxofusp data at ASCO 2026 Annual Meeting

Enhertu recommended for EU approval in previously treated HER2 positive metastatic solid tumours

OSE Immunotherapeutics reports positive Phase 2 ovarian cancer trial results

Whitehawk Therapeutics signs new option agreement for use of CPT113 linker-payload

4basebio secures clinical supply agreement for Phase II immunotherapy trial

FDA approves MEKanistic Therapeutics' IND for MTX-531

Matter Bio submits first IND application for Lm-LLO-TT

Myosin Therapeutics doses first patient in Phase 1/2 study of MT-125 in GBM

Nanjing Leads Biolabs receives Chinese approval for pivotal Phase III trial of PD-L1/4-1BB bispecific antibody

ImmunityBio secures US patent portfolio covering ANKTIVA combination therapy through to 2035

CelLBxHealth partners with AdventHealth on cancer monitoring studies

Racura Oncology reports positive Safety Review Committee recommendation in ongoing CPACS trial of RC220

SN BioScience reports first patient dosed in global Phase 1b/2 clinical trial of SNB-101

US FDA approves Datar Cancer Genetics' comprehensive genomic profiling assay for solid tumours

Intensity Therapeutics receives Cancer Treatment Technology Innovator of the Year award